Lemaitre Vascular (LMAT) Misses Q1 EPS by 2c, Raises FY 2018 EPS Guidance, Lowers FY 2018 Rev Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Benchmark Upgrades LeMaitre Vascular (LMAT) to Buy; 'Sell-Off Overdone; 2019 Outlook Should Improve'
April 26, 2018 1:32 PM EDTBenchmark upgraded LeMaitre Vascular (NASDAQ: LMAT) from Hold to Buy.
For an analyst ratings summary and ratings history on LeMaitre Vascular click here. For more ratings news on LeMaitre Vascular click here.
Shares of LeMaitre Vascular closed at $39.01 yesterday.
... MoreStifel Downgrades LeMaitre Vascular (LMAT) to Hold
April 26, 2018 3:53 AM EDTStifel downgraded LeMaitre Vascular (NASDAQ: LMAT) from Buy to Hold with a price target of $34.00 (from $40.00).
Analyst Rick Wise cites visibility for stepping ot the sideline as he struggles to articulate the company's top-line and operating income growth drivers.
For an analyst... More
